clinical trial · NCT04125836
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
AcromegalyCAM2029 (octreotide subcutaneous depot)
brief summary
The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Patients completing the main part of the trial will be offered 52 weeks continued open-label treatment in an extension part.
started
Oct 10, 2019
primary completion
Apr 24, 2025
completion
Apr 24, 2025
last updated
Dec 22, 2025
official title
A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol